Early experience with tixagevimab/cilgavimab pre-exposure prophylaxis in patients with immune-mediated inflammatory disease undergoing B cell depleting therapy and those with inborn errors of humoral immunity

Detalles Bibliográficos
Autores principales: Calabrese, Cassandra, Kirchner, Elizabeth, Villa-Forte, Alexandra, Hajj-Ali, Rula A, Moss, Brandon P, Fernandez, James P, Calabrese, Leonard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Infections
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485640/
https://www.ncbi.nlm.nih.gov/pubmed/36123015
http://dx.doi.org/10.1136/rmdopen-2022-002557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9485640/
https://www.ncbi.nlm.nih.gov/pubmed/36123015
http://dx.doi.org/10.1136/rmdopen-2022-002557

Ejemplares similares